You just read:

Perosphere and Daiichi Sankyo Enter into a Clinical Trial Agreement to Evaluate the Efficacy and Safety of PER977 to Reverse the Anticoagulant Activity of the Investigational, Oral, Once-Daily Factor Xa Inhibitor Edoxaban

News provided by

Daiichi Sankyo Company (TSE: 4568) and Perosphere Inc

25 Apr, 2013, 12:11 BST